Finance

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

The 700,000 square-foot facility is expected to create 400 high-wage manufacturing jobs once operational.

Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.

Navigating technology and regulatory shifts in pharma revenue management.

Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how regulatory, patent, and reimbursement challenges are slowing venture investment in GLP-1 and psychedelic addiction therapies.

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly will assume responsibility for further development and commercialization of the novel platform.

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies, including antibody-drug conjugates.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

The company will be adding a new manufacturing site to its NJ campus for the drug Adstiladrin.

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in radiopharmaceutical production and distribution.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Marcel Botha, CEO of 10XBeta, discusses finding a balance between the need for cost-efficiency and the need to build domestic manufacturing capacity for essential medical devices.

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, identifies innovative strategies and solutions for addressing the rising cost of medications and improving patient access.

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.